Alar Pharmaceuticals

6785.TWO

8.11 USD

-0.10

-1.22%

Overview

Last close

8.11 usd

Market cap

541.67M usd

52 week high

9.63 usd

52 week low

3.40 usd

Target price

9.44 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

13594.572

Price/Book Value

6.9672

Enterprise Value

473.20M usd

EV/Revenue

11597.7294

EV/EBITDA

413.1064

Key financials

Revenue TTM

40801.04 usd

Gross Profit TTM

29404.1 usd

EBITDA TTM

-4.16M usd

Earnings per Share

-0.01 usd

Dividend

0.01 usd

Total assets

78.46M usd

Net debt

-20.81M usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.